Cytokine & Growth Factor Reviews最新文献

筛选
英文 中文
Growth differentiation factor 11: A new hope for the treatment of cardiovascular diseases 生长分化因子11:治疗心血管疾病的新希望
IF 13 2区 医学
Cytokine & Growth Factor Reviews Pub Date : 2023-06-01 DOI: 10.1016/j.cytogfr.2023.06.007
Yingchun Shao , Yanhong Wang , Jiazhen Xu , Yang Yuan , Dongming Xing
{"title":"Growth differentiation factor 11: A new hope for the treatment of cardiovascular diseases","authors":"Yingchun Shao ,&nbsp;Yanhong Wang ,&nbsp;Jiazhen Xu ,&nbsp;Yang Yuan ,&nbsp;Dongming Xing","doi":"10.1016/j.cytogfr.2023.06.007","DOIUrl":"10.1016/j.cytogfr.2023.06.007","url":null,"abstract":"<div><p>Growth differentiation factor 11<span> (GDF11) is a member of the transforming growth factor-β superfamily that has garnered significant attention due to its anti-cardiac aging properties. Many studies have revealed that GDF11 plays an indispensable role in the onset of cardiovascular diseases (CVDs). Consequently, it has emerged as a potential target and novel therapeutic agent for CVD treatment. However, currently, no literature reviews comprehensively summarize the research on GDF11 in the context of CVDs. Therefore, herein, we comprehensively described GDF11’s structure, function, and signaling in various tissues. Furthermore, we focused on the latest findings concerning its involvement in CVD development and its potential for clinical translation as a CVD treatment. We aim to provide a theoretical basis for the prospects and future research directions of the GDF11 application regarding CVDs.</span></p></div>","PeriodicalId":11132,"journal":{"name":"Cytokine & Growth Factor Reviews","volume":null,"pages":null},"PeriodicalIF":13.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9973543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent progress and prospects for anti-cytokine therapy in preclinical and clinical acute lung injury 抗细胞因子治疗临床前和临床急性肺损伤的研究进展及展望
IF 13 2区 医学
Cytokine & Growth Factor Reviews Pub Date : 2023-06-01 DOI: 10.1016/j.cytogfr.2023.07.002
Guilherme Pasetto Fadanni , João Batista Calixto
{"title":"Recent progress and prospects for anti-cytokine therapy in preclinical and clinical acute lung injury","authors":"Guilherme Pasetto Fadanni ,&nbsp;João Batista Calixto","doi":"10.1016/j.cytogfr.2023.07.002","DOIUrl":"10.1016/j.cytogfr.2023.07.002","url":null,"abstract":"<div><p><span>Acute respiratory distress syndrome<span> (ARDS) is a heterogeneous cause of respiratory failure that has a rapid onset, a high mortality rate, and for which there is no effective pharmacological treatment. Current evidence supports a critical role of excessive inflammation in ARDS, resulting in several cytokines, cytokine receptors<span>, and proteins within their downstream signalling pathways being putative therapeutic targets. However, unsuccessful trials of anti-inflammatory </span></span></span>drugs<span><span> have thus far hindered progress in the field. In recent years, the prospects of precision medicine and therapeutic targeting of cytokines coevolving into effective treatments<span> have gained notoriety. There is an optimistic and growing understanding of ARDS subphenotypes as well as advances in treatment strategies and clinical trial design. Furthermore, large trials of anti-cytokine drugs </span></span>in patients<span> with COVID-19 have provided an unprecedented amount of information that could pave the way for therapeutic breakthroughs. While current clinical and nonclinical ARDS research suggest relatively limited potential in monotherapy<span> with anti-cytokine drugs, combination therapy has emerged as an appealing strategy and may provide new perspectives on finding safe and effective treatments. Accurate evaluation of these drugs, however, also relies on well-founded experimental research and the implementation of biomarker-guided stratification in future trials. In this review, we provide an overview of anti-cytokine therapy for acute lung injury and ARDS, highlighting the current preclinical and clinical evidence for targeting the main cytokines individually and the therapeutic prospects for combination therapy.</span></span></span></p></div>","PeriodicalId":11132,"journal":{"name":"Cytokine & Growth Factor Reviews","volume":null,"pages":null},"PeriodicalIF":13.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9974081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
mTOR in programmed cell death and its therapeutic implications mTOR与程序性细胞死亡及其治疗意义
IF 13 2区 医学
Cytokine & Growth Factor Reviews Pub Date : 2023-06-01 DOI: 10.1016/j.cytogfr.2023.06.002
Yawen Xie, Xianli Lei, Guoyu Zhao, Ran Guo, Na Cui
{"title":"mTOR in programmed cell death and its therapeutic implications","authors":"Yawen Xie,&nbsp;Xianli Lei,&nbsp;Guoyu Zhao,&nbsp;Ran Guo,&nbsp;Na Cui","doi":"10.1016/j.cytogfr.2023.06.002","DOIUrl":"10.1016/j.cytogfr.2023.06.002","url":null,"abstract":"<div><p>Mechanistic target of rapamycin (mTOR), a highly conserved serine/threonine kinase, is involved in cellular metabolism, protein synthesis, and cell death. Programmed cell death (PCD) assists in eliminating aging, damaged, or neoplastic cells, and is indispensable for sustaining normal growth, fighting pathogenic microorganisms, and maintaining body homeostasis. mTOR has crucial functions in the intricate signaling pathway network of multiple forms of PCD. mTOR can inhibit autophagy, which is part of PCD regulation. Cell survival is affected by mTOR through autophagy to control reactive oxygen species production and the degradation of pertinent proteins. Additionally, mTOR can regulate PCD in an autophagy-independent manner by affecting the expression levels of related genes and phosphorylating proteins. Therefore, mTOR acts through both autophagy-dependent and -independent pathways to regulate PCD. It is conceivable that mTOR exerts bidirectional regulation of PCD, such as ferroptosis, according to the complexity of signaling pathway networks, but the underlying mechanisms have not been fully explained. This review summarizes the recent advances in understanding mTOR-mediated regulatory mechanisms in PCD. Rigorous investigations into PCD-related signaling pathways have provided prospective therapeutic targets that may be clinically beneficial for treating various diseases.</p></div>","PeriodicalId":11132,"journal":{"name":"Cytokine & Growth Factor Reviews","volume":null,"pages":null},"PeriodicalIF":13.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10342677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Modulation of IL-33/ST2 signaling as a potential new therapeutic target for cardiovascular diseases 调节IL-33/ST2信号作为心血管疾病潜在的新治疗靶点
IF 13 2区 医学
Cytokine & Growth Factor Reviews Pub Date : 2023-06-01 DOI: 10.1016/j.cytogfr.2023.06.003
Punniyakoti Veeraveedu Thanikachalam , Srinivasan Ramamurthy , Poojitha Mallapu , Sudhir Rama Varma , Jayaraj Narayanan , Mohammed AS Abourehab , Prashant Kesharwani
{"title":"Modulation of IL-33/ST2 signaling as a potential new therapeutic target for cardiovascular diseases","authors":"Punniyakoti Veeraveedu Thanikachalam ,&nbsp;Srinivasan Ramamurthy ,&nbsp;Poojitha Mallapu ,&nbsp;Sudhir Rama Varma ,&nbsp;Jayaraj Narayanan ,&nbsp;Mohammed AS Abourehab ,&nbsp;Prashant Kesharwani","doi":"10.1016/j.cytogfr.2023.06.003","DOIUrl":"10.1016/j.cytogfr.2023.06.003","url":null,"abstract":"<div><p><span>IL-33 belongs to the IL-1 family of cytokines, which function as inducers of Th2 cytokine production<span> by binding with ST2L and IL-1RAcP. This, in turn, activates various signaling pathways, including the mitogen-activated protein kinase (MAPK), the inhibitor of Kappa-B kinase (IKK) pathway, and the phospholipase </span></span><span>D</span><span><span><span>-sphingosine kinase pathway. IL-33 has demonstrated protective effects against various cardiovascular diseases (CVDs) by inducing Th2 cytokines and promoting alternative activating M2 polarization. However, the soluble decoy form of ST2 (sST2) mitigates the biological effects of IL-33, exacerbating CVDs. Furthermore, IL-33 also plays a significant role in the development of asthma, arthritis, atopic dermatitis, and </span>anaphylaxis through the activation of Th2 cells and mast cells. In this review, we aim to demonstrate the protective role of IL-33 against CVDs from 2005 to the present and explore the potential of serum soluble ST2 (sST2) as a diagnostic biomarker for CVDs. Therefore, IL-33 holds promise as a potential therapeutic target for the </span>treatment of CVDs.</span></p></div>","PeriodicalId":11132,"journal":{"name":"Cytokine & Growth Factor Reviews","volume":null,"pages":null},"PeriodicalIF":13.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10024789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Targeting the metabolism and immune system in pancreatic ductal adenocarcinoma: Insights and future directions 针对胰腺导管腺癌的代谢和免疫系统:见解和未来方向
IF 13 2区 医学
Cytokine & Growth Factor Reviews Pub Date : 2023-06-01 DOI: 10.1016/j.cytogfr.2023.06.006
Dhana Sekhar Reddy Bandi , Sujith Sarvesh , Batoul Farran , Ganji Purnachandra Nagaraju , Bassel F. El-Rayes
{"title":"Targeting the metabolism and immune system in pancreatic ductal adenocarcinoma: Insights and future directions","authors":"Dhana Sekhar Reddy Bandi ,&nbsp;Sujith Sarvesh ,&nbsp;Batoul Farran ,&nbsp;Ganji Purnachandra Nagaraju ,&nbsp;Bassel F. El-Rayes","doi":"10.1016/j.cytogfr.2023.06.006","DOIUrl":"10.1016/j.cytogfr.2023.06.006","url":null,"abstract":"<div><p><span><span>Pancreatic cancer, specifically </span>pancreatic ductal adenocarcinoma<span> (PDAC), presents a challenging landscape due to its complex nature and the highly immunosuppressive<span><span> tumor microenvironment<span> (TME). This immunosuppression severely limits the effectiveness of immune-based </span></span>therapies<span>. Studies have revealed the critical role of immunometabolism in shaping the TME and influencing PDAC progression. </span></span></span></span>Genetic alterations<span><span>, lysosomal dysfunction, gut microbiome<span> dysbiosis, and altered metabolic pathways have been shown to modulate immunometabolism in PDAC. These metabolic alterations can significantly impact </span></span>immune cell<span> functions, including T-cells, myeloid-derived suppressor cells (MDSCs), and macrophages, evading anti-tumor immunity. Advances in immunotherapy offer promising avenues for overcoming immunosuppressive TME and enhancing patient outcomes. This review highlights the challenges and opportunities for future research in this evolving field. By exploring the connections between immunometabolism, genetic alterations, and the microbiome in PDAC, it is possible to tailor novel approaches capable of improving immunotherapy outcomes and addressing the limitations posed by immunosuppressive TME. Ultimately, these insights may pave the way for improved treatment options and better outcomes for PDAC patients.</span></span></p></div>","PeriodicalId":11132,"journal":{"name":"Cytokine & Growth Factor Reviews","volume":null,"pages":null},"PeriodicalIF":13.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10342691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Pathogenic mechanisms of glucocorticoid-induced osteoporosis 糖皮质激素诱发骨质疏松症的发病机制。
IF 13 2区 医学
Cytokine & Growth Factor Reviews Pub Date : 2023-04-01 DOI: 10.1016/j.cytogfr.2023.03.002
Meng Chen , Wenyu Fu , Huiyun Xu , Chuan-ju Liu
{"title":"Pathogenic mechanisms of glucocorticoid-induced osteoporosis","authors":"Meng Chen ,&nbsp;Wenyu Fu ,&nbsp;Huiyun Xu ,&nbsp;Chuan-ju Liu","doi":"10.1016/j.cytogfr.2023.03.002","DOIUrl":"10.1016/j.cytogfr.2023.03.002","url":null,"abstract":"<div><p><span><span><span>Glucocorticoid<span><span> (GC) is one of the most prescribed medicines to treat various inflammatory and autoimmune diseases. However, high doses and long-term use of GCs lead to multiple adverse effects, particularly glucocorticoid-induced osteoporosis (GIO). Excessive GCs exert detrimental effects on bone cells, including </span>osteoblasts, </span></span>osteoclasts, and </span>osteocytes, leading to impaired bone formation and resorption. The actions of exogenous GCs are considered to be strongly cell-type and dose dependent. GC excess inhibits the proliferation and differentiation of osteoblasts and enhances the </span>apoptosis<span><span> of osteoblasts and osteocytes, eventually contributing to reduced bone formation. Effects of GC excess on osteoclasts mainly include enhanced osteoclastogenesis, increased lifespan and number of mature osteoclasts, and diminished osteoclast apoptosis, which result in increased </span>bone resorption. Furthermore, GCs have an impact on the secretion of bone cells, subsequently disturbing the process of osteoblastogenesis and osteoclastogenesis. This review provides timely update and summary of recent discoveries in the field of GIO, with a particular focus on the effects of exogenous GCs on bone cells and the crosstalk among them under GC excess.</span></p></div>","PeriodicalId":11132,"journal":{"name":"Cytokine & Growth Factor Reviews","volume":null,"pages":null},"PeriodicalIF":13.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518688/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10592779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Role of cellular senescence in inflammatory lung diseases 细胞衰老在炎性肺病中的作用
IF 13 2区 医学
Cytokine & Growth Factor Reviews Pub Date : 2023-04-01 DOI: 10.1016/j.cytogfr.2023.02.001
Cong Xie , Mai Maititusun Ya Likun , Qing-li Luo , Jing-cheng Dong
{"title":"Role of cellular senescence in inflammatory lung diseases","authors":"Cong Xie ,&nbsp;Mai Maititusun Ya Likun ,&nbsp;Qing-li Luo ,&nbsp;Jing-cheng Dong","doi":"10.1016/j.cytogfr.2023.02.001","DOIUrl":"10.1016/j.cytogfr.2023.02.001","url":null,"abstract":"<div><p><span>Cellular senescence<span>, a characteristic sign of aging, classically refers to permanent cell proliferation arrest and is a vital contributor to the pathogenesis of cancer and age-related illnesses. A lot of imperative scientific research has shown that senescent cell aggregation and the release of senescence-associated secretory phenotype (SASP) components can cause lung </span></span>inflammatory diseases<span> as well. In this study, the most recent scientific progress on cellular senescence and phenotypes was reviewed, including their impact on lung inflammation<span> and the contributions of these findings to understanding the underlying mechanisms and clinical relevance of cell and developmental biology. Within a dozen pro-senescent stimuli, the irreparable DNA damage, oxidative stress<span>, and telomere erosion are all crucial in the long-term accumulation of senescent cells, resulting in sustained inflammatory stress activation in the respiratory system. An emerging role for cellular senescence in inflammatory lung diseases was proposed in this review, followed by the identification of the main ambiguities, thus further understanding this event and the potential to control cellular senescence and pro-inflammatory response activation. In addition, novel therapeutic strategies for the modulation of cellular senescence that might help to attenuate inflammatory lung conditions and improve disease outcomes were also presented in this research.</span></span></span></p></div>","PeriodicalId":11132,"journal":{"name":"Cytokine & Growth Factor Reviews","volume":null,"pages":null},"PeriodicalIF":13.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9942682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Preexisting immunity: Barrier or bridge to effective oncolytic virus therapy? 先前存在的免疫:有效溶瘤病毒治疗的屏障还是桥梁?
IF 13 2区 医学
Cytokine & Growth Factor Reviews Pub Date : 2023-04-01 DOI: 10.1016/j.cytogfr.2023.01.002
Christianne Groeneveldt , Jasper van den Ende , Nadine van Montfoort
{"title":"Preexisting immunity: Barrier or bridge to effective oncolytic virus therapy?","authors":"Christianne Groeneveldt ,&nbsp;Jasper van den Ende ,&nbsp;Nadine van Montfoort","doi":"10.1016/j.cytogfr.2023.01.002","DOIUrl":"10.1016/j.cytogfr.2023.01.002","url":null,"abstract":"<div><p>Oncolytic viruses (OVs) represent a highly promising treatment strategy for a wide range of cancers, by mediating both the direct killing of tumor cells as well as mobilization of antitumor immune responses. As many OVs circulate in the human population, preexisting OV-specific immune responses are prevalent. Indeed, neutralizing antibodies (NAbs) are abundantly present in the human population for commonly used OVs, such as Adenovirus type 5 (Ad5), Herpes Simplex Virus-1 (HSV-1), Vaccinia virus, Measles virus, and Reovirus. This review discusses (pre)clinical evidence regarding the effect of preexisting immunity against OVs on two distinct aspects of OV therapy; OV infection and spread, as well as the immune response induced upon OV therapy. Combined, this review provides evidence that consideration of preexisting immunity is crucial in realizing the full potential of the highly promising therapeutic implementation of OVs. Future investigation of current gaps in knowledge highlighted in this review should yield a more complete understanding of this topic, ultimately allowing for better and more personalized OV therapies.</p></div>","PeriodicalId":11132,"journal":{"name":"Cytokine & Growth Factor Reviews","volume":null,"pages":null},"PeriodicalIF":13.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9570201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron SARS-CoV-2组粒对中和抗体的免疫逃避
IF 13 2区 医学
Cytokine & Growth Factor Reviews Pub Date : 2023-04-01 DOI: 10.1016/j.cytogfr.2023.03.001
Lidong Wang , Michelle Møhlenberg , Pengfei Wang , Hao Zhou
{"title":"Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron","authors":"Lidong Wang ,&nbsp;Michelle Møhlenberg ,&nbsp;Pengfei Wang ,&nbsp;Hao Zhou","doi":"10.1016/j.cytogfr.2023.03.001","DOIUrl":"10.1016/j.cytogfr.2023.03.001","url":null,"abstract":"<div><p>Since its emergence at the end of 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the infection of more than 600 million people worldwide and has significant damage to global medical, economic, and political structures. Currently, a highly mutated variant of concern, SARS-CoV-2 Omicron, has evolved into many different subvariants mainly including BA.1, BA.2, BA.3, BA.4/5, and the recently emerging BA.2.75.2, BA.2.76, BA.4.6, BA.4.7, BA.5.9, BF.7, BQ.1, BQ.1.1, XBB, XBB.1, etc. Mutations in the N-terminal domain (NTD) of the spike protein, such as A67V, G142D, and N212I, alter the antigenic structure of Omicron, while mutations in the spike receptor binding domain (RBD), such as R346K, Q493R, and N501Y, increase the affinity for angiotensin-converting enzyme 2 (ACE2). Both types of mutations greatly increase the capacity of Omicron to evade immunity from neutralizing antibodies, produced by natural infection and/or vaccination. In this review, we systematically assess the immune evasion capacity of SARS-CoV-2, with an emphasis on the neutralizing antibodies generated by different vaccination regimes. Understanding the host antibody response and the evasion strategies employed by SARS-CoV-2 variants will improve our capacity to combat newly emerging Omicron variants.</p></div>","PeriodicalId":11132,"journal":{"name":"Cytokine & Growth Factor Reviews","volume":null,"pages":null},"PeriodicalIF":13.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985919/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9926381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
Multiple post-translational modifications ensure EGFR functionality: Potential therapeutic targets to overcome its drug-resistance mutations 多种翻译后修饰确保EGFR功能:克服其耐药突变的潜在治疗靶点
IF 13 2区 医学
Cytokine & Growth Factor Reviews Pub Date : 2023-04-01 DOI: 10.1016/j.cytogfr.2023.03.003
Qiangqiang He , Meiyu Qu , Hangyang Bao , Yana Xu , Tingyu Shen , Dan Tan , Muhammad Qasim Barkat , Chengyun Xu , Ling-Hui Zeng , Ximei Wu
{"title":"Multiple post-translational modifications ensure EGFR functionality: Potential therapeutic targets to overcome its drug-resistance mutations","authors":"Qiangqiang He ,&nbsp;Meiyu Qu ,&nbsp;Hangyang Bao ,&nbsp;Yana Xu ,&nbsp;Tingyu Shen ,&nbsp;Dan Tan ,&nbsp;Muhammad Qasim Barkat ,&nbsp;Chengyun Xu ,&nbsp;Ling-Hui Zeng ,&nbsp;Ximei Wu","doi":"10.1016/j.cytogfr.2023.03.003","DOIUrl":"10.1016/j.cytogfr.2023.03.003","url":null,"abstract":"<div><p><span>Epidermal growth factor receptor (EGFR) mutation is the most common driver mutation in non-small cell lung cancer (NSCLC). The first-line therapy for advanced NSCLC patients with EGFR-sensitive mutation is the EGFR </span>tyrosine kinase<span> inhibitor (EGFR-TKI). However, most NSCLC patients with EGFR mutation will develop resistant mutations in EGFR-TKI therapy. With further studies, resistance mechanisms represented by EGFR-T790M mutations have revealed the impact of EGFR mutations in situ on EGFR-TKIs sensitivity. The third-generation EGFR-TKIs inhibit both EGFR-sensitive mutations and T790M mutations. The emergence of novel mutations such as EGFR-C797S and EGFR-L718Q may decrease efficacy. Searching for new targets to overcome EGFR-TKI resistance becomes a key challenge. Therefore, an in-depth understanding of the regulatory mechanisms of EGFR is essential to find novel targets to overcome drug-resistant mutations in EGFR-TKIs. EGFR, as a receptor-type tyrosine kinase, undergoes homo/heterodimerization and autophosphorylation<span> upon binding to ligands, which activates multiple downstream signaling pathways<span>. Interestingly, there is growing evidence that the kinase activity of EGFR is affected not only by phosphorylation but also by various post-translational modifications (PTMs, such as S-palmitoylation, S-nitrosylation, Methylation<span>, etc.). In this review, we systematically review the effects of different protein PTMs on EGFR kinase activity and its functionality and suggest that influencing EGFR kinase activity by modulating multiple EGFR sites are potential targets to overcome EGFR-TKIs resistance mutations.</span></span></span></span></p></div>","PeriodicalId":11132,"journal":{"name":"Cytokine & Growth Factor Reviews","volume":null,"pages":null},"PeriodicalIF":13.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9926375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信